China Cardiac Marker Testing Market (2026-2031)
The China Cardiac Marker Testing Market was valued at $320.4 Million in 2026 and projected to reach to $625.9 Million by 2031, representing a compound annual growth rate of 14.3%. China's cardiac marker testing market is poised for exceptional growth through 2031, driven by demographic shifts toward an aging population and escalating cardiovascular disease incidence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Cardiac Marker Testing Market Trends and Insights
- This accelerated growth trajectory reflects China's aging population, rising cardiovascular disease prevalence, and substantial investments in healthcare infrastructure modernization.
- China's cardiac marker testing sector is outpacing global averages, driven by increased adoption of point-of-care testing and enhanced diagnostic capabilities across urban and emerging healthcare facilities. The market in China is characterized by growing demand for rapid, accurate cardiac biomarker detection in both hospital and outpatient settings.
- China's healthcare system expansion and government initiatives to improve cardiac care access are fueling laboratory automation and advanced testing technologies.
- Between 2026 and 2031, China is expected to consolidate its position as a key regional market, with rising healthcare expenditure and clinical awareness supporting sustained double-digit growth in cardiac marker testing volumes and revenue..
Key Market Statistics
- CAGR (2026-2031) 14.3% CAGR
- Market Size, 2026 ~USD 320.4 Million
- Forecast, 2031 ~USD 625.9 Million
- Country China
China Cardiac Marker Testing Market Overview
Rapid Market Expansion :
China's cardiac marker testing market is projected to grow from USD 320.4 million in 2026 to USD 625.9 million by 2031, representing a robust 14.3% CAGR that significantly outpaces the global growth rate of 10.3%.
Aging Population Dynamics :
China's rapidly aging demographic is driving increased cardiovascular disease prevalence, creating sustained demand for cardiac marker testing across hospitals, diagnostic centers, and primary care facilities nationwide.
Healthcare Infrastructure Investment :
Substantial government investments in modernizing China's healthcare infrastructure, including rural health systems and diagnostic capabilities, are expanding access to cardiac marker testing technologies and services.
Regional Market Leadership :
China's cardiac marker testing sector is outpacing global benchmarks, positioning the country as a key growth engine within Asia-Pacific and attracting significant pharmaceutical and diagnostic device manufacturer attention.
China Cardiac Marker Testing Market Dynamics
- Government healthcare modernization initiatives and increased diagnostic spending are expanding market accessibility across urban and rural regions.
- The market's 14.3% CAGR reflects strong adoption of advanced testing technologies and growing clinical awareness among healthcare providers. Looking ahead, China's market will benefit from technological innovations in point-of-care testing, integration with digital health platforms, and expanded insurance coverage for cardiac diagnostics.
- Rising disposable incomes and preventive healthcare awareness among the middle class will further accelerate demand.
- Strategic partnerships between international diagnostic manufacturers and Chinese healthcare institutions will enhance market penetration and drive competitive innovation..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- China's cardiac marker testing market is valued at USD 320.4 million in 2026 and will grow to USD 625.9 million by 2031, representing a 14.3% CAGR.
- China's market growth significantly outpaces the global CAGR of 10.3%, driven by aging demographics and cardiovascular disease burden.
- Point-of-care testing adoption and healthcare infrastructure modernization are accelerating cardiac marker testing demand across China.
- China's government-backed healthcare initiatives and rising clinical awareness are expected to sustain double-digit growth through 2031.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
China Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
CHINA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC INSTITUTES | 37.8 | 39.8 | 45 | 51 | 58 | 66.2 | 75.9 | 87.1 | 14.1 |
| LABORATORY TESTING FACILITIES | 245.6 | 255.9 | 286.1 | 320.5 | 360.4 | 406.7 | 460.5 | 521.8 | 12.8 |
| POINT-OF-CARE TESTING | 115.7 | 123.2 | 140.6 | 160.9 | 184.9 | 213.3 | 246.8 | 286 | 15.3 |
| TOTAL | 399.1 | 418.9 | 471.7 | 532.4 | 603.3 | 686.3 | 783.2 | 894.8 | 13.7 |
Target Audience
- Diagnostic Device Manufacturers : In vitro diagnostics and cardiac marker testing equipment manufacturers need China-specific market data to identify growth opportunities, assess market entry feasibility, and develop localized product strategies for this rapidly expanding segment.
- Healthcare System Operators : Hospital networks, diagnostic centers, and healthcare providers in China require market intelligence to optimize cardiac testing service offerings, justify capital investments in diagnostic infrastructure, and align with market growth trends.
- Pharmaceutical & Biotech Companies : Organizations developing cardiac biomarkers and related therapeutics need China market insights to understand diagnostic adoption rates, identify clinical partnership opportunities, and support regulatory and commercialization strategies.
- Private Equity & Investment Firms : Investors evaluating healthcare opportunities in China require detailed market analysis to assess investment returns, identify acquisition targets in cardiac diagnostics, and understand growth catalysts and market dynamics.
- Healthcare Policy & Government Agencies : Chinese health authorities and policy makers need market data to inform healthcare infrastructure planning, diagnostic service expansion initiatives, and resource allocation decisions for cardiovascular disease prevention and management.
Key Companies in the China Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China (USD 320.4M in 2026, USD 625.9M in 2031) with verified 14.3% CAGR to support investment decisions, business planning, and competitive positioning in this high-growth market.
- China-Specific Growth Drivers : Understand localized factors including aging demographics, cardiovascular disease prevalence trends, and government healthcare modernization initiatives that differentiate China's market from global patterns and competitors.
- Strategic Market Entry Planning : Leverage detailed China market intelligence to develop targeted go-to-market strategies, identify partnership opportunities with local healthcare providers, and optimize product positioning for maximum market penetration.
- Competitive Intelligence : Benchmark your organization against China's market dynamics and regional competitors with comprehensive data on market structure, growth trajectories, and emerging opportunities in cardiac diagnostics.
- Investment & Expansion Justification : Present stakeholders with credible, data-driven evidence of China's cardiac marker testing market potential to secure funding, justify resource allocation, and support expansion or acquisition strategies in this high-CAGR segment.
Frequently asked questions
What is the current size of China's cardiac marker testing market?
China's cardiac marker testing market is valued at USD 320.4 million in 2026 and is projected to reach USD 625.9 million by 2031.
What is the growth rate of China's cardiac marker testing market?
China's cardiac marker testing market is growing at a CAGR of 14.3% from 2026 to 2031, significantly exceeding the global average of 10.3%.
What factors are driving growth in China's cardiac marker testing market?
Key drivers include China's aging population, rising cardiovascular disease prevalence, healthcare infrastructure modernization, point-of-care testing adoption, and government-backed healthcare initiatives.
How does China's cardiac marker testing market compare to global trends?
China's market is growing faster than the global average, with a 14.3% CAGR compared to the global 10.3%, reflecting strong regional demand and healthcare investment.
What testing technologies are gaining traction in China's cardiac marker market?
Point-of-care testing, laboratory automation, and advanced biomarker detection technologies are increasingly adopted across China's hospital and outpatient healthcare settings.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report